11 results
To assess the feasibility of a larger study comparing HFNO with NIV as first line treatment in hypercapnic, acidotic AECOPD.
To investigate the role of the immune system in the etiology and prognosis in an acute ischemic stroke (or TIA) in young stroke patients.
To compare postamputation pain (phantom limb pain and residual limb pain) one year postoperatively in patients receiving a lower extremity amputation with standard neurectomy versus those who received targeted muscle reinnervation.
The main objective of this trial is to determine whether reusable catheters are not less efficient as single use catheters, measured by symptomatic UTIs. Secondary objectives are adverse events like hospital admissions due to UTIs, urethral damage/…
Our objective is to compare the efficacy of early chest tube removal combined with single-shot PVB versus standard treatment (chest tube for at least 3 days and thoracic epidural analgesia (TEA)) after surgery for PSP. Efficacy is defined as…
The goal of this study is to investigate which treatment(-s) lead to the best outcome by using existing variation of practice.
To evaluate and compare the survival outcome of patients with first recurrence of glioblastoma undergoing surgical debulking/resection followed by either implantation of the SC9 device and repeat BBB opening in association with carboplatin…
To compare the degree of osteoarthritis in the knee after 10 years, in patients with non-obstructive meniscal tear, between meniscal surgery and exercise therapy treatment.
In this study we will compare a hybrid DEB strategy with a conventional bailout 2-stent strategy (TAP/T-stenting or Culotte) in patients with a bifurcation lesion with sub-optimal side-branch result. The primary endpoint will be the composite…
To determine whether CDT in high-risk PE relative to systemic thrombolysis is:- more effective and safer in terms of a reduction of the composite endpoint on all-cause mortality and adverse events defined as treatment failure, major&…
Determine the safety (oncological outcome and toxicity) of an comprehensive treatment combining recent advances in the treatment of high risk prostate cancer